EHA 2019 | How will the sequencing of treatments for DLBCL change in the future?

At the 24th Congress of the European Hematology Association (EHA), Ulrich Jäger from the Medical University of Vienna, Vienna, AT, discusses how to decide what treatments to use, and when, for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Professor Jäger notes that we now have many options for treating patients with lymphomas, such as DLBCL and the question is how to determine the appropriate treatment for each patient when they relapse or become refractory to treatment. A few options were described, such as CAR T, bi-specific antibodies, conjugated antibodies and chemotherapeutic agents.

Professor Jäger raised several questions; how to bridge patients to receive CAR T? Will patients who receive bispecific antibodies need CAR T?

Additionally, it was noted that there is a data issue in this treatment dilemma. After CAR T relapse, some patients survive a long time indicating some treatments rescue patients after CAR T, however currently we do not know what these therapies are, so there is work to do here.